BioTuesdays

Category - Markets

William Blair starts Solid Biosciences at OP

William Blair launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating. The stock closed at $14.25 on March 27. Solid Biosciences is a development-stage biotechnology company transitioning to...

Gracell Biotechnologies

Evercore starts Gracell Biotech at OP

Evercore ISI initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “outperform” rating and no price target. The stock was quoted at $5.43 midday on Nov. 27. Gracell is developing a unique CAR-T construct...

Annovis Logo

Brookline starts Annovis Bio at buy; PT $35

Brookline Capital Markets initiated coverage of Annovis Bio (NASDAQ:ANVS) with a “buy” rating and price target of $35. The stock was quoted at $5.85 midday on Nov. 10. Annovis is developing treatments for...

Myomo

AGP ups Myomo to buy; PT $4.60 from $2

Alliance Global Partners upgraded Myomo (NYSE:MYO) to “buy” and raised its price target to $4.60 from $2. The stock was quoted at $1.85 midday on Nov.8. Myomo develops and markets the MyoPro product line of lightweight...

Adlai-Nortye-Logo

Cantor starts Adlai Nortye at OW; PT $30

Cantor Fitzgerald launched coverage of Adlai Nortye (NASDAQ:ANL) with an “overweight” rating and price target of $30. The stock closed at $8.52 on Oct 24. The company is focused on the discovery and development of...

JMP starts Vigil Neuroscience at MO; PT $23

JMP Securities initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “market outperform” rating and price target of $23. The stock was quoted at $6.50 midday on Oct 18. Vigil is developing novel therapies for...